Jack Singer
29Patents
12h-index
20Co-inventors
81Inventor score
Filing activity: Jun 5, 1985 → Jan 31, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8129348B2 | Conjugates of biologically active proteins having a modified in vivo half-life | Emerging Cross-Sectional Technologies | 49 | Active |
| US5648357A | Enatiomerically pure hydroxylated xanthine compounds | Emerging Cross-Sectional Technologies | 37 | Expired |
| US5859018A | Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF, and VEGF | Human Necessities | 37 | Expired |
| US5795898A | Method for treating diseases mediated by cellular proliferation in response to PDGF,EGF,FGF and VEGF | Human Necessities | 26 | Expired |
| US5929081A | Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF and VEGF | Human Necessities | 23 | Expired |
| US5585380A | Modulation of cellular response to external stimuli | Human Necessities | 23 | Expired |
| US5580873A | Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases | Emerging Cross-Sectional Technologies | 17 | Expired |
| US6420374B1 | Use of xanthines as immunosuppressants and to inhibit allograft reactions | Human Necessities | 15 | Expired |
| US5792772A | Enatiomerically pure hydroxylated xanthine compounds | Emerging Cross-Sectional Technologies | 14 | Expired |
| US5652243A | Methods of using enantiomerically pure hydroxylated xanthine compounds | Emerging Cross-Sectional Technologies | 14 | Expired |
| US5629315A | Treatment of diseases using enantiomerically pure hydroxylated xanthine compounds | Emerging Cross-Sectional Technologies | 13 | Expired |
| US5621102A | Process for preparing enantiomerically pure xanthine derivatives | Emerging Cross-Sectional Technologies | 13 | Expired |
| US5620984A | Enatiomerically pure hydroxylated xanthine compounds to treat inflammatory diseases | Emerging Cross-Sectional Technologies | 12 | Expired |
| US5580874A | Enatiomerically pure hydroxylated xanthine compounds | Emerging Cross-Sectional Technologies | 12 | Expired |
| US5739138A | Enantiomerically pure hydroxylated xanthine compounds to treat autoimmune diabetes | Emerging Cross-Sectional Technologies | 12 | Expired |
| US5856331A | Method for preventing tissue injury from hypoxia | Human Necessities | 10 | Expired |
| US5859017A | Method for inhibiting mast cell and basophil activation | Human Necessities | 6 | Expired |
| US5670507A | Method for reversing multiple drug resistant phenotype | Human Necessities | 6 | Expired |
| US7153864B2 | Polyglutamic acid-camptothecin conjugates and methods of preparation | Chemistry; Metallurgy | 6 | Expired |
| US5965564A | Enantiomerically pure hydroxylated xanthine compounds | Emerging Cross-Sectional Technologies | 4 | Expired |
| US5985926A | Method for inhibiting intracellular viral replication | Emerging Cross-Sectional Technologies | 4 | Expired |
| US5567704A | R-enatiomerically pure hydroxylated xanthine compounds to treat baldness | Emerging Cross-Sectional Technologies | 4 | Expired |
| US4593031A | Method of treating depression | Human Necessities | 2 | Expired |
| US5612349A | Enantiomerically pure hydroxylated xanthine compounds to treat shock symptoms | Emerging Cross-Sectional Technologies | 2 | Expired |
| US6057328A | Method for treating hyperoxia | Human Necessities | 1 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.